myelodysplastic syndromes/nauzea

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 19 výsledky

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

In preclinical studies Pevonedistat has shown significant single agent activity against mouse xenograft models of AML cell Line HL-60. Also this effect seemed to be synergistically enhanced by combining it with Azacitidine. In clinical arena, Pevonedistat has shown single agent activity in heavily

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The active metabolite of SGI-110 (2'-deoxy-5-azacytidylyl-(3'→5')-2'-deoxyguanosine sodium salt), a dinucleotide, is decitabine, an FDA-approved agent for the treatment of myelodysplastic syndromes. SGI-110 is resistant to modification by cytidine deaminase, a common pathway of decitabine metabolism

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

INTRODUCTION 1.1 Background Myelodysplastic syndrome (MDS) is characterized by deficiencies in blood cell production that can lead to anemia, which may necessitate regular transfusions of red blood cells (RBCs) as supportive therapy. While this treatment can be life-saving, since the body has no

Maintenance Lenalidomide in Lymphoma

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Describe succinctly and clearly the past findings which justify the plan for this project. A summary of the relevant literature in the area of interest and reports of previous studies should be included. For majority of lymphoma patients who relapse after complete response or who are primary

Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Study Drug Administration: If you are found to be eligible to take part in this study, on Days 1-4 of every cycle, you will receive azacitidine by vein over 15-30 minutes. You may receive drugs to help prevent nausea and vomiting before you receive your dose of azacitidine. On Days 5-7 of every

Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Rationale: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic HSCT. The combination of a calcineurin inhibitor and methotrexate has been the standard GVHD prophylactic regimen for the past 20 years. However, the incidence of acute GVHD remains high,

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Hematopoietic stem cell transplantation (SCT) is an effective treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). For patients transplanted in first remission or with low risk MDS, approximately 60% of patients have achieved long-term disease free survival. Patients with

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

In the United States, the incidence of acute myeloid leukemia (AML) is approximately 3.5 cases per 100,000 persons per year. Approximately 13,000 people were diagnosed with AML in 2009 and 9,000 died of the disease, making AML the 6th leading cause of cancer death. Over the past three decades, AML

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This is a three-part phase 1 study in which nineteen to one hundred two patients with Low, Intermediate-1, Intermediate-2, or High risk MDS will receive oral doses of ON 01910.Na Concentrate as escalating single or multiple doses (70mg to 700 mg bid) up to 14 days of a 21-day cycle. Part I:

5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The Study Drugs: Azacitidine is designed to block certain proteins that stop the function of tumor-fighting genes. By blocking the "bad" proteins, the tumor-fighting genes may be able to work better. Lenalidomide is designed to change the immune system. It may also interfere with the development of

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Chemotherapy-related nausea and vomiting is a frequent problem among patients with leukemia that can lead to further medical problems, such as malnutrition, dehydration, electrolyte imbalance, and a lower quality of life. Cytarabine, one of the drugs that is used to treat AML and high-risk MDS, is

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The Study Drugs: Gemtuzumab ozogamicin is designed to attach to Sialic acid-binding Ig-like lectin 3 (CD33), a certain protein that is often found in leukemia cells, causing them to die. Decitabine is designed to damage the DNA (the genetic material) of cells, which may cause cancer cells to

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Cytarabine is a drug that is used to treat AML and high-risk MDS. It is known to cause nausea and/or vomiting. All patients that receive cytarabine also receive drugs to help prevent these side effects. The Study Drugs: Ondansetron is designed to block the action of serotonin, a substance in the

Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The Study Drugs: Azacitidine is designed to block certain genes in cancer cells whose job is to stop the function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes may be able to work better. Vorinostat is designed to cause chemical changes in different groups of

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

The Study Drugs: Gemtuzumab ozogamicin is designed to attach to Sialic acid-binding Ig-like lectin 3 (CD33), a certain protein that is often found in leukemia cells, causing them to die. Decitabine is designed to damage the Deoxyribonucleic acid (DNA) (the genetic material) of cells, which may cause

Predchádzajúce
1
2
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume